Payment overview · 2025
General Payments
$211.17
9 reported records · 6 companies
Healthcare provider profile · identity verified
Shaan Valji, MD
Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1598285884
Verified facts
What the public records show
CMS Open Payments records show Shaan Valji, MD received $211.17 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 38.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $80.81 | 38.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.35 | 19.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.47 | 12.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.91 | 11.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.66 | 10.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.97 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.17 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.81 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 329 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 199 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 188 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 177 | 46 |
| Omeprazole | Omeprazole | 174 | 44 |
| Alprazolam | Alprazolam | 164 | 20 |
| Trazodone Hcl | Trazodone Hcl | 158 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 36 |
| Lisinopril | Lisinopril | 147 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 135 | 21 |
| Potassium Chloride | Potassium Chloride | 121 | 36 |
| Furosemide | Furosemide | 120 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 118 | 70 |
| Ozempic | Semaglutide | 114 | 24 |
| Meloxicam | Meloxicam | 111 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 26 |
| Lorazepam | Lorazepam | 102 | 19 |
| Metformin Hcl | Metformin Hcl | 98 | 23 |
| Jardiance | Empagliflozin | 95 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 83 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 19 |
| Buspirone Hcl | Buspirone Hcl | 68 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 14 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Diazepam | Diazepam | 66 | 19 |
| Clonazepam | Clonazepam | 63 | 14 |
| Anastrozole | Anastrozole | 61 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 15 |
| Montelukast Sodium | Montelukast Sodium | 58 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 58 | 12 |
| Losartan Potassium | Losartan Potassium | 57 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 14 |
| Fluconazole | Fluconazole | 52 | 24 |
| Ibuprofen | Ibuprofen | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Prednisone | Prednisone | 46 | 25 |
| Eliquis | Apixaban | 45 | 12 |
| Pregabalin | Pregabalin | 45 | 16 |
| Estradiol | Estradiol | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 41 | 15 |
| Linzess | Linaclotide | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 13 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 16 |
| Glyxambi | Empagliflozin/Linagliptin | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 12 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Gemtesa | Vibegron | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Easy Comfort Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.17 · 9 records | ABBVIE INC. | FREESTYLE LIBRE 3, Korlym, LEQVIO, Ozempic, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error